ARTICLE | Clinical News

Simdax: Completed Ph III enrollment

November 30, 2016 4:15 PM UTC

Tenax completed enrollment of 880 patients in the double-blind, placebo-controlled, North American Phase III LEVO-CTS trial evaluating IV levosimendan. The trial enrolled patients undergoing coronary artery bypass graft (CABG) surgery or mitral valve surgery who are at risk for developing LCOS. Patients will receive 0.2 µg/kg/minute levosimendan for 1 hour, followed by a 0.1 µg/kg/minute dose for 23 hours. The company has an SPA from FDA for LEVO-CTS. ...

BCIQ Target Profiles

Potassium channel